Vis enkel innførsel

dc.contributor.authorPenaforte-Saboia, Jaquellyne G
dc.contributor.authorCouri, Carlos Eduardo Barra
dc.contributor.authorFernandes, Virginia Oliveira
dc.contributor.authorMontenegro, Ana Paula Dias Rangel
dc.contributor.authorBatista, Livia Aline De Araujo
dc.contributor.authorZajdenverg, Lenita
dc.contributor.authorNegrato, Carlos Antonio
dc.contributor.authorMalmegrim, Kelen Cristina Ribeiro
dc.contributor.authorMoraes, Daniela Aparecida
dc.contributor.authorDias, Juliana Bernardes Elias
dc.contributor.authorOliveira, Maria Carolina
dc.contributor.authorHussain, Akhtar
dc.contributor.authorGomes, Marilia Brito
dc.contributor.authorMontenegro, Renan Magalhaes
dc.date.accessioned2020-06-18T11:27:38Z
dc.date.available2020-06-18T11:27:38Z
dc.date.created2020-03-02T14:32:16Z
dc.date.issued2019
dc.identifier.citationPenaforte-Saboia, J. G., Couri, C. E. B., Fernandes, V. O., Montenegro, A. P. D. R., Batista, L. A. D. A., Zajdenverg, L., Negrato, C. A., Malmegrim, K. C. R., Moraes, D. A., Dias, J. B. E., Oliveira, M. C., Hussain, A., Gomes, M. B. & Montenegro Jr., R. M. (2019). Lower insulin-dose adjusted A1c (IDAA1c) is associated with less complications in Individuals with Type 1 Diabetes treated with hematopoetic stem-cell transplantation and conventional therapy. Frontiers in Endocrinology, 10: 747. doi:en_US
dc.identifier.issn1664-2392
dc.identifier.urihttps://hdl.handle.net/11250/2658637
dc.description.abstractObjective: To evaluate the association between insulin-dose adjusted A1C (IDAA1c) and microvascular complications (MC) and hypoglycemia in a representative Brazilian population of Type 1 diabetes mellitus (T1DM) patients. Research Design and Methods: This was a cross-sectional study based on a previous study, “Microvascular Complications in Type 1 Diabetes: a comparative analysis of patients treated with autologous nonmyeloablative hematopoietic stem-cell transplantation (AHST) and conventional medical therapy (CT)”. The 168 patients in that study (144 from CT plus 24 from AHST) were re-subdivided into two groups, according to their IDAA1c values (30 patients had IDAA1c ≤ 9; 138 had IDAA1c > 9). Then, the prevalence of MC (diabetic renal disease, neuropathy, and retinopathy), hypoglycemia (blood glucose <60 mg/dL), and severe hypoglycemic (episode of hypoglycemia that required the assistance of another person to treat) events were compared between the groups. The groups were well-matched on these factors: duration of disease, sex, and age at the time of diagnosis of T1DM. Results: After an average of 8 years after diagnosis, only 6.6% (2/30) of the patients from IDAA1c ≤ 9 group developed any MC, whereas 21.0% (29/138) from the IDAA1c > 9 group had at least one complication (p = 0.044). Regarding hypoglycemic events, the proportion of individuals who reported at least 1 episode of hypoglycemia in the last month was 43.3 and 64.7% from the IDAA1c ≤ 9 and IDAA1c > 9 groups, respectively (p = 0.030). Regarding severe hypoglycemia, the proportion of patients presenting at least one episode in the last month and the rate of episode/patient/month were similar between groups (6.7 vs. 13.2%; p = 0.535; and 0.1/patient/month vs. 0.25/patient/month; p = 0.321). Conclusion: In a representative Brazilian population of T1DM patients, those with IDAA1c ≤ 9 presented a lower frequency of MC, as well as fewer episodes of hypoglycemia, in the month prior to the analysis.en_US
dc.language.isoengen_US
dc.publisherFrontiersen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleLower insulin-dose adjusted A1c (IDAA1c) is associated with less complications in Individuals with Type 1 Diabetes treated with hematopoetic stem-cell transplantation and conventional therapyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2019 The Author(s)en_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Endokrinologi: 774en_US
dc.source.pagenumber7en_US
dc.source.volume10en_US
dc.source.journalFrontiers in Endocrinologyen_US
dc.identifier.doi10.3389/fendo.2019.00747
dc.identifier.cristin1798972


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal